Insight Molecular Diagnostics’ (IMDX) Equal Weight Rating Reiterated at Stephens

Stephens reissued their equal weight rating on shares of Insight Molecular Diagnostics (NASDAQ:IMDX – Free Report) in a research report released on Wednesday,Benzinga reports. They currently have a $4.00 price target on the stock.

IMDX has been the topic of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insight Molecular Diagnostics in a report on Monday, September 21st. Needham & Company LLC reiterated a “buy” rating and issued a $9.00 price objective on shares of Insight Molecular Diagnostics in a research report on Tuesday, August 18th. Finally, Wall Street Zen downgraded Insight Molecular Diagnostics from a “hold” rating to a “sell” rating in a report on Saturday, October 3rd. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $5.75.

Read Our Latest Research Report on IMDX

Insight Molecular Diagnostics Trading Up 17.5%

NASDAQ IMDX opened at $1.95 on Wednesday. The stock has a market capitalization of $63.80 million, a price-to-earnings ratio of -1.56 and a beta of 1.90. The business’s 50 day moving average is $3.05 and its two-hundred day moving average is $4.43. Insight Molecular Diagnostics has a 12-month low of $1.50 and a 12-month high of $7.51.

Insight Molecular Diagnostics (NASDAQ:IMDX – Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($0.19) EPS for the quarter. The firm had revenue of $0.56 million during the quarter.

Insider Buying and Selling

In related news, major shareholder Broadwood Partners, L.P. acquired 3,428,571 shares of the firm’s stock in a transaction that occurred on Tuesday, November 17th. The shares were purchased at an average price of $1.75 per share, with a total value of $5,999,999.25. Following the completion of the acquisition, the insider owned 16,113,455 shares in the company, valued at approximately $28,198,546.25. This represents a 27.03% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 2.21% of the company’s stock.

Insight Molecular Diagnostics Company Profile

(Get Free Report)

Oncocyte Corporation, now known as Insight Molecular Diagnostics, Inc. (NASDAQ: IMDX), is a molecular diagnostics company focused on monitoring organ transplants. Its tests analyze donor-derived cell-free DNA in a transplant recipient’s blood to help assess graft health and identify signs of potential injury or rejection. The company’s VitaGraft tests include assays for kidney and liver transplant monitoring. These laboratory-developed tests are processed through the company’s clinical laboratory and are intended to provide clinicians with information that can complement other aspects of post-transplant care.

See Also

Analyst Recommendations for Insight Molecular Diagnostics (NASDAQ:IMDX)

Receive News & Ratings for Insight Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insight Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.